Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

@inproceedings{Maldonado2017CompassionateUO,
  title={Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis},
  author={Mauricio Sarmiento Maldonado and Pablo Ram{\'i}rez Villanueva and Pablo Bert{\'i}n Cort{\'e}s-Monroy and Veronica Jara Arias and Katherine Soto Donoso and Pablo Uribe Gonzalez and Mauricio Ocqueteau Tachini and Jos{\'e} Antonio P{\'e}rez-Sim{\'o}n},
  booktitle={Experimental hematology & oncology},
  year={2017}
}
Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. Cases presentation In this report we present… CONTINUE READING